Search Results

CuraSen Therapeutics, Inc. announced that it will present additional positive Phase 2a data with its combination adrenergic activator, CST-2032/CST-107.

CuraSen Therapeutics, Inc. announced that it has received a strategic investment of up to $5.8 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease.

CuraSen Therapeutics, Inc. announced that it will present Phase 2 clinical data showing improvements in cognition and mood in Parkinson’s disease patients treated with CST-103/CST-107, a novel combination therapy that restores adrenergic stimulus to the brain.

CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced today positive top-line safety, tolerability and proof of concept data, with early efficacy benefit, in a Phase 2 clinical trial with CST-103 in patients with Parkinson’s disease (PD) or mild cognitive impairment (MCI).

CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has begun dosing patients in a Phase 2a clinical trial with CST-2032, a novel, oral beta-2 adrenoceptor (β2-AR) agonist.

CuraSen Therapeutics, Inc. announced data from a Phase 1b trial showing that patients with mild cognitive impairment or Parkinson’s disease experienced a significant increase in regional cerebral blood flow (rCBF) in key areas of the brain after being treated with CST-103, a beta-2 adrenoceptor agonist.